Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04534205




Registration number
NCT04534205
Ethics application status
Date submitted
27/08/2020
Date registered
1/09/2020
Date last updated
14/06/2024

Titles & IDs
Public title
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Scientific title
An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT)
Secondary ID [1] 0 0
2020-001400-41
Secondary ID [2] 0 0
BNT113-01
Universal Trial Number (UTN)
Trial acronym
AHEAD-MERIT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Unresectable Head and Neck Squamous Cell Carcinoma 0 0
Metastatic Head and Neck Cancer 0 0
Recurrent Head and Neck Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Head and neck
Infection 0 0 0 0
Other infectious diseases
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - BNT113
Treatment: Other - Pembrolizumab

Experimental: Part A (Safety run-In) - BNT113 + Pembrolizumab - Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.

Experimental: Part B (Randomized phase) - BNT113 + Pembrolizumab - BNT113 in combination with pembrolizumab.

Active comparator: Part B (Randomized phase) - Pembrolizumab monotherapy - Pembrolizumab monotherapy.


Treatment: Other: BNT113
IV injection

Treatment: Other: Pembrolizumab
IV infusion
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumab
Timepoint [1] 0 0
up to 27 months
Primary outcome [2] 0 0
Part B - Overall Survival (OS)
Timepoint [2] 0 0
up to 48 months
Primary outcome [3] 0 0
Part B - Overall response rate (ORR) assessed by blinded independent central review (BICR)
Timepoint [3] 0 0
up to 48 months
Secondary outcome [1] 0 0
Overall response rate (ORR) by investigator's assessment
Timepoint [1] 0 0
up to 48 months
Secondary outcome [2] 0 0
Part B - Progression free survival (PFS)
Timepoint [2] 0 0
up to 48 months
Secondary outcome [3] 0 0
Part A - Disease control rate (DCR)
Timepoint [3] 0 0
up to 48 months
Secondary outcome [4] 0 0
Duration of Response (DOR)
Timepoint [4] 0 0
up to 48 months
Secondary outcome [5] 0 0
Part B - Occurrence of TEAEs - BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy
Timepoint [5] 0 0
up to 27 months
Secondary outcome [6] 0 0
Part B - Occurrence of dose reduction, delay, and discontinuation of trial treatments due to TEAEs
Timepoint [6] 0 0
up to 27 months

Eligibility
Key inclusion criteria
Pre-screening phase (optional - patients can alternatively perform tumor biomarker testing as part of the main screening phase):

* Patients must sign the written pre-screening informed consent form (ICF) before any pre-screening procedures.
* Patients must have histologically confirmed recurrent or metastatic HNSCC with no prior systemic anticancer therapy administered in the recurrent or metastatic (R/M) setting.
* Patients have a clinical situation at a relatively high risk of developing R/M disease.
* Patients do not meet any exclusion criteria for the main clinical trial, except for time-dependent (e.g., prior systemic treatment in the prior 6 months) or potentially reversible conditions that in the opinion of the investigator will be resolved prior to potential enrollment into the main phase.

Main trial:

* Patients must sign the written informed consent form before any screening procedure. Informed consent must be documented before any trial-specific screening procedure is performed.
* Patients must be aged =18 years on the date of signing the informed consent.
* Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the trial.
* Patients who present histologically confirmed recurrent or metastatic HPV16+ HNSCC that is considered incurable by local therapies.
* Patients who have a tumor that expresses PD-L1 [CPS =1] as determined by the approved test PD-L1 IHC 22C3 pharmDx kit performed and evaluated according to the manufacturer's specifications and relevant regulatory approvals.
* The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
* Patients must not have had prior systemic anticancer therapy administered in the incurable recurrent or metastatic setting. Systemic therapy which was completed more than 6 months prior to randomization, if given as part of multimodal treatment for locally advanced disease, is allowed.
* Patients who have measurable disease based on RECIST 1.1 as determined by the site and confirmed by BICR. Tumor lesions situated in a previously irradiated area may be considered measurable, if progression has been demonstrated in such lesions disease by RECIST 1.1.
* Patients have Eastern Cooperative Oncology Group (ECOG) performance status =1.
* Patients have adequate bone marrow function as defined by hematological parameters.
* Patients have adequate hepatic function.
* Patients should have adequate kidney function, assessed by the estimated glomerular filtration rate (eGFR) =30 mL/min/1.73m^2 using the Chronic Kidney Disease Epidemiology Collaboration (CPK-EPI) equation.
* Patients should be stable with adequate coagulation, as determined by the investigator.
* All patients must provide a tumor tissue sample (formalin fixed paraffin embedded [FFPE] blocks or both slides and curls) from archival tissue, or fresh biopsy if a biopsy is performed as part of the patient's standard clinical practice before the first dose of trial treatment.
* Women of childbearing potential (WOCBP) must not be pregnant. WOCBP, male patients who are sexually active with WOCBP and female partners of male patients should use a highly effective method of contraception up to at least 6 months after receiving the last dose of trial treatment, and should agree not to donate eggs (ova, oocytes) or sperm.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Medical conditions:

* Patients are pregnant or breastfeeding.
* Patients present primary tumor site of nasopharynx (any histology).
* Patients with uncontrolled intercurrent illness, including but not limited to:

* Ongoing or active infection which requires systemic treatment with antibiotics on the first dose of trial treatment.
* Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), myocardial infarction within 3 months before screening, unstable angina pectoris, or cardiac arrhythmia.
* Arterial thrombosis or pulmonary embolism within =6 months before the start of trial treatment, if not on a stable dose of anticoagulants or if in the opinion of the investigator contra-indicates trial inclusion.
* Evidence or history of interstitial lung disease that, in the opinion of the investigator, is a contraindication for treatment with pembrolizumab, or active non-infectious pneumonitis.
* Uncontrolled hypertension defined as systolic blood pressure =160 mmHg and/or diastolic blood pressure =100 mmHg, despite optimal medical management. Patients with arterial hypertension need to be on stable anti-hypertensive medication for at least 4 weeks prior to trial entry.
* Known primary immunodeficiencies.
* Evidence or history of significant autoimmune disease that (a) required treatment with systemic immunosuppressive treatments, (b) was associated with ongoing treatment with corticosteroids, or (c) was associated with a record of significant end-organ dysfunction (even if transient), which in the opinion of the investigator may suggest increased risk for immune-related AEs.
* Patients with prior allogeneic stem cell or solid organ transplantation.
* Any other disease, metabolic dysfunction, physical examination finding, and/or laboratory finding giving reasonable suspicion of a disease or condition that in the opinion of the investigator contraindicates the use of an investigational drug or may render the patient at high risk for complications.
* Patients with a known allergy, hypersensitivity, or intolerance to BNT113 or its excipients, or to pembrolizumab or its excipients.
* Patients who have had a splenectomy.
* Patients who have had major surgery (e.g., requiring general anesthesia) within 4 weeks before screening, or have not fully recovered from surgery, or have major surgery planned during the time of trial participation.
* Patients who have a known history or a positive test at screening of any of the following:

1. Human immunodeficiency virus (HIV) 1 or 2. Inclusion is allowed if HIV 1/2 infection is adequately controlled and stable on a highly effective antiviral regimen.
2. Hepatitis B infection, as defined by the presence of hepatitis B surface antigen (HbsAg) or hepatitis B virus (HBV) DNA positivity. Testing of HBV DNA is mandatory if hepatitis B core antibody is positive.
3. Hepatitis C (unless considered cured).
* Patients with another primary malignancy that has not been in complete remission for at least 2 years, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, non-invasive basal or non-invasive squamous cell skin cancer, localized prostate cancer, non-invasive superficial bladder cancer or breast ductal carcinoma in situ).
* Patients with any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

Prior/concomitant therapy:

* Patients who have received or currently receive the following therapy/medication:

1. Chronic systemic immunosuppressive treatment including corticosteroid treatment (prednisone >10 mg daily orally [PO] or intravenously [IV], or equivalent) in the 7 days prior to the first dose of trial treatment.
2. Prior treatment with other immune modulating agents that was (a) within fewer than 4 weeks (28 days) or 5 half-lives of the agent (whichever is longer) prior to the first dose of BNT113, or (b) associated with immune-mediated AEs that have not resolved prior to the first dose of BNT113 or that pose an additional risk of on-trial complications, per investigator's assessment, or (c) associated with toxicity that resulted in discontinuation of the immune-modulating agent and that poses an additional risk of on-trial complications, per investigator's assessment.
3. Prior treatment with live attenuated vaccines within 4 weeks before the first dose of BNT113.
4. Prior treatment with an investigational drug (including investigational vaccines) within 4 weeks or 5 half-lives of the agent (whichever is longer) before the planned first dose of BNT113.
5. Ongoing treatment with therapeutic PO or IV antibiotics. • Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) may be enrolled.
* Prior treatment with anti-cancer immunomodulating agents, such as blockers of programmed death receptor-1 (PD-1), PD-L1, tumor necrosis factor receptor superfamily member 9 (TNRSF9, 4 1BB, CD137), OX 40, therapeutic vaccines, cytokine treatments, or any investigational agent within 4 weeks or 5 half-lives of the agent (whichever is longer) before the first dose of BNT113.
* Treatment with non-systemic anti-cancer therapy (e.g., radiotherapy or surgery) within 2 weeks prior to randomization.

* Note: Prior treatment with bone resorptive therapy, such as bisphosphonates (e.g., pamidronate, zoledronic acid) and denosumab, is allowed.

Other comorbidities:

* Current evidence of Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade >1 toxicity before the start of treatment, except for hair loss and those Grade 2 toxicities listed as permitted in other eligibility criteria. Patients with Grade 2 neuropathy may be eligible at investigator's discretion.
* Current evidence of new or growing brain or spinal metastases during screening. Patients with known brain or spinal metastases may be eligible if they:

1. had radiotherapy or another appropriate therapy for the brain or spinal metastases,
2. have no neurological symptoms (excluding Grade =2 neuropathy),
3. have no evidence of clinical or radiological progression within 4 weeks before signing the informed consent,
4. do not require steroid therapy within 7 days before randomization or are undergoing slow steroid tapering, currently at doses =10 mg and neurologically stable.
5. spinal bone metastases are allowed, unless imminent fracture or cord compression is anticipated.

Other exclusions:

* Patients who have previously been enrolled in this trial (rescreening is allowed once).
* Patients with substance abuse or known medical, psychological, or social conditions that in the opinion of the investigator may interfere with the patient's participation in the trial or evaluation of the trial results.
* Patients affiliated with the investigational site (e.g., a close relative of the investigator or dependent person, such as an employee or student of the trial site) or sponsor. For patients meeting this criterion, a prospective exception and eventual contingencies to be put in place may be defined on a case-by-case basis by the local Institutional Review Board.

Tumor-related conditions:

* Patients that have disease suitable for local therapy administered with curative intent.
* Patients that have a life expectancy of less than 3 months and/or have rapidly progressive disease, as assessed by the treating investigator.
* Patients with high-burden of visceral metastatic disease or location in anatomically critical areas (e.g., causing significant biliary or respiratory obstruction), that in the opinion of the investigator may benefit from treatment with chemotherapy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/01/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/05/2028
Actual
Sample size
Target
285
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Cancer Research SA - Adelaide
Recruitment hospital [2] 0 0
Bankstown-Lidcombe Hospital - Bankstown
Recruitment hospital [3] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [4] 0 0
Coffs Harbour Hospital - Coffs Harbour
Recruitment hospital [5] 0 0
St Vincent's Hospital - Fitzroy
Recruitment hospital [6] 0 0
Royal North Shore Hospital - Saint Leonards
Recruitment hospital [7] 0 0
John Flynn Private Hospital - Tugun
Recruitment hospital [8] 0 0
Southern Medical Day Care Centre - Wollongong
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
2200 - Bankstown
Recruitment postcode(s) [3] 0 0
5042 - Bedford Park
Recruitment postcode(s) [4] 0 0
2450 - Coffs Harbour
Recruitment postcode(s) [5] 0 0
VIC 3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
2065 - Saint Leonards
Recruitment postcode(s) [7] 0 0
4224 - Tugun
Recruitment postcode(s) [8] 0 0
2500 - Wollongong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
New Mexico
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Oregon
Country [11] 0 0
United States of America
State/province [11] 0 0
Washington
Country [12] 0 0
Argentina
State/province [12] 0 0
Berazategui
Country [13] 0 0
Argentina
State/province [13] 0 0
Ciudad de Buenos Aires
Country [14] 0 0
Argentina
State/province [14] 0 0
Córdoba
Country [15] 0 0
Argentina
State/province [15] 0 0
La Rioja
Country [16] 0 0
Argentina
State/province [16] 0 0
Pergamino
Country [17] 0 0
Argentina
State/province [17] 0 0
Rosario
Country [18] 0 0
Argentina
State/province [18] 0 0
San Miguel De Tucumán
Country [19] 0 0
Argentina
State/province [19] 0 0
Viedma
Country [20] 0 0
Austria
State/province [20] 0 0
Graz
Country [21] 0 0
Austria
State/province [21] 0 0
Innsbruck
Country [22] 0 0
Austria
State/province [22] 0 0
Linz
Country [23] 0 0
Austria
State/province [23] 0 0
Salzburg
Country [24] 0 0
Belgium
State/province [24] 0 0
Bruxelles
Country [25] 0 0
Belgium
State/province [25] 0 0
Gent
Country [26] 0 0
Belgium
State/province [26] 0 0
Liège
Country [27] 0 0
Brazil
State/province [27] 0 0
Barretos
Country [28] 0 0
Brazil
State/province [28] 0 0
Caxias Do Sul
Country [29] 0 0
Brazil
State/province [29] 0 0
Curitiba
Country [30] 0 0
Brazil
State/province [30] 0 0
Ijuí
Country [31] 0 0
Brazil
State/province [31] 0 0
Ipatinga
Country [32] 0 0
Brazil
State/province [32] 0 0
Porto Alegre
Country [33] 0 0
Brazil
State/province [33] 0 0
Rio De Janeiro
Country [34] 0 0
Brazil
State/province [34] 0 0
Salvador
Country [35] 0 0
Brazil
State/province [35] 0 0
São José Do Rio Preto
Country [36] 0 0
Brazil
State/province [36] 0 0
São Paulo
Country [37] 0 0
Brazil
State/province [37] 0 0
Vila Mariana
Country [38] 0 0
Canada
State/province [38] 0 0
Edmonton
Country [39] 0 0
Canada
State/province [39] 0 0
Montreal
Country [40] 0 0
Canada
State/province [40] 0 0
Montréal
Country [41] 0 0
Canada
State/province [41] 0 0
Toronto
Country [42] 0 0
Chile
State/province [42] 0 0
Santiago
Country [43] 0 0
Chile
State/province [43] 0 0
Temuco
Country [44] 0 0
Czechia
State/province [44] 0 0
Olomouc
Country [45] 0 0
Czechia
State/province [45] 0 0
Prague 8 - Liben
Country [46] 0 0
France
State/province [46] 0 0
Bordeaux
Country [47] 0 0
France
State/province [47] 0 0
Dijon Cedex
Country [48] 0 0
France
State/province [48] 0 0
Le Mans
Country [49] 0 0
France
State/province [49] 0 0
Marseille
Country [50] 0 0
France
State/province [50] 0 0
Nantes
Country [51] 0 0
France
State/province [51] 0 0
Paris
Country [52] 0 0
France
State/province [52] 0 0
Tours
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Frankfurt am Main
Country [55] 0 0
Germany
State/province [55] 0 0
Hamburg
Country [56] 0 0
Germany
State/province [56] 0 0
Heidelberg
Country [57] 0 0
Germany
State/province [57] 0 0
Köln
Country [58] 0 0
Germany
State/province [58] 0 0
Leipzig
Country [59] 0 0
Germany
State/province [59] 0 0
München
Country [60] 0 0
Germany
State/province [60] 0 0
Münster
Country [61] 0 0
Germany
State/province [61] 0 0
Rostock
Country [62] 0 0
Germany
State/province [62] 0 0
Saarbruecken
Country [63] 0 0
Germany
State/province [63] 0 0
Tübingen
Country [64] 0 0
Germany
State/province [64] 0 0
Würzburg
Country [65] 0 0
Hungary
State/province [65] 0 0
Budapest
Country [66] 0 0
Hungary
State/province [66] 0 0
Debrecen
Country [67] 0 0
Hungary
State/province [67] 0 0
Zalaegerszeg
Country [68] 0 0
Italy
State/province [68] 0 0
Brescia
Country [69] 0 0
Italy
State/province [69] 0 0
Legnago
Country [70] 0 0
Italy
State/province [70] 0 0
Milano
Country [71] 0 0
Italy
State/province [71] 0 0
Napoli
Country [72] 0 0
Italy
State/province [72] 0 0
Novara
Country [73] 0 0
Italy
State/province [73] 0 0
Siena
Country [74] 0 0
Italy
State/province [74] 0 0
Udine
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Daejeon
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Hwasun
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Seoul
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Suwon-si
Country [79] 0 0
Mexico
State/province [79] 0 0
Region Chiapas
Country [80] 0 0
Mexico
State/province [80] 0 0
Chihuahua
Country [81] 0 0
Mexico
State/province [81] 0 0
Ciudad De México
Country [82] 0 0
Mexico
State/province [82] 0 0
Guadalajara
Country [83] 0 0
Mexico
State/province [83] 0 0
Monterrey
Country [84] 0 0
Mexico
State/province [84] 0 0
Veracruz
Country [85] 0 0
Mexico
State/province [85] 0 0
Yucatán
Country [86] 0 0
Poland
State/province [86] 0 0
Gdansk
Country [87] 0 0
Poland
State/province [87] 0 0
Gdynia
Country [88] 0 0
Poland
State/province [88] 0 0
Gliwice
Country [89] 0 0
Poland
State/province [89] 0 0
Konin
Country [90] 0 0
Poland
State/province [90] 0 0
Kraków
Country [91] 0 0
Poland
State/province [91] 0 0
Poznan
Country [92] 0 0
Poland
State/province [92] 0 0
Wroclaw
Country [93] 0 0
Portugal
State/province [93] 0 0
Braga
Country [94] 0 0
Portugal
State/province [94] 0 0
Coimbra
Country [95] 0 0
Portugal
State/province [95] 0 0
Gaia
Country [96] 0 0
Portugal
State/province [96] 0 0
Lisboa
Country [97] 0 0
Portugal
State/province [97] 0 0
Porto
Country [98] 0 0
Spain
State/province [98] 0 0
Barcelona
Country [99] 0 0
Spain
State/province [99] 0 0
Girona
Country [100] 0 0
Spain
State/province [100] 0 0
Jaén
Country [101] 0 0
Spain
State/province [101] 0 0
Madrid
Country [102] 0 0
Spain
State/province [102] 0 0
Majadahonda
Country [103] 0 0
Spain
State/province [103] 0 0
Malaga
Country [104] 0 0
Spain
State/province [104] 0 0
Palma de Mallorca
Country [105] 0 0
Spain
State/province [105] 0 0
Pamplona
Country [106] 0 0
Spain
State/province [106] 0 0
Valencia
Country [107] 0 0
Spain
State/province [107] 0 0
Zaragoza
Country [108] 0 0
Sweden
State/province [108] 0 0
Goteborg
Country [109] 0 0
Sweden
State/province [109] 0 0
Lund
Country [110] 0 0
Sweden
State/province [110] 0 0
Umeå
Country [111] 0 0
Taiwan
State/province [111] 0 0
Changhua
Country [112] 0 0
Taiwan
State/province [112] 0 0
Kaohsiung City
Country [113] 0 0
Taiwan
State/province [113] 0 0
Kaohsiung
Country [114] 0 0
Taiwan
State/province [114] 0 0
Taichung
Country [115] 0 0
Taiwan
State/province [115] 0 0
Taipei
Country [116] 0 0
Turkey
State/province [116] 0 0
Adana
Country [117] 0 0
Turkey
State/province [117] 0 0
Ankara
Country [118] 0 0
Turkey
State/province [118] 0 0
Edirne
Country [119] 0 0
Turkey
State/province [119] 0 0
Istanbul
Country [120] 0 0
Turkey
State/province [120] 0 0
Izmir
Country [121] 0 0
Turkey
State/province [121] 0 0
Malatya
Country [122] 0 0
Turkey
State/province [122] 0 0
Yüregir
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Cardiff
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Glasgow
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Liverpool
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Oxford
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
BioNTech SE
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand -1 (PD-L1) with combined positive score (CPS) =1.

This trial has two parts.

Part A, an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.

Part B, the Randomized part of the trial to generate pivotal efficacy and safety data of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy in the first line setting in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 with CPS =1.

For Part B, an optional pre-screening phase is available for all patients where patients' tumor samples may be submitted for central HPV16 DNA and central PD-L1 expression testing prior to screening into the main trial.
Trial website
https://clinicaltrials.gov/study/NCT04534205
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
BioNTech Responsible Person
Address 0 0
BioNTech SE
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BioNTech clinical trials patient information
Address 0 0
Country 0 0
Phone 0 0
+49 6131 9084
Fax 0 0
Email 0 0
patients@biontech.de
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04534205